Welcome to our dedicated page for Nexalin Tech news (Ticker: NXLIW), a resource for investors and traders seeking the latest updates and insights on Nexalin Tech stock.
Nexalin Technology Inc. (NXLIW) pioneers non-invasive neurostimulation therapies for mental health conditions, offering drug-free alternatives through its transcranial electrical stimulation (TES) and deep intracranial frequency stimulation (DIFS) technologies. This page provides investors, researchers, and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic initiatives shaping the future of neurohealth innovation.
Access real-time announcements covering FDA clearances, partnership agreements, clinical trial outcomes, and product development progress. Our curated repository ensures you stay informed about Nexalin’s contributions to treating anxiety, depression, insomnia, and related neurological disorders through bioelectronic medical solutions.
Discover updates categorized for clarity: earnings reports detailing financial health, peer-reviewed study publications validating therapeutic efficacy, and collaborations advancing digital health integration. Each release is vetted for relevance to investor decision-making and industry trends in neurostimulation.
Bookmark this page for streamlined access to authoritative NXLIW news. Regularly updated content supports informed analysis of the company’s role in transforming mental health treatment paradigms through safe, clinically validated technologies.
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) provided a business update on March 27, 2023, highlighting progress in clinical trials for new neurostimulation devices aimed at treating mental health disorders. The Gen-2 and Gen-3 devices are expected to improve treatment efficacy without medication. Revenue for 2022 reached $1.3 million, a significant increase from $0.1 million in 2021, primarily due to more device sales. While operating expenses decreased to $2.8 million from $6.1 million, the net loss narrowed to $1.7 million per share. The company reports having $7.0 million in liquidity for future operations.
Nexalin Technology announced the appointment of Michael Nketiah as Senior Vice President of Quality, Clinical, and Regulatory. Nketiah brings over 23 years of experience in regulatory affairs and clinical operations, specifically with the FDA. His expertise will support the company in accelerating FDA clearance for its Generation 2 and Generation 3 neurostimulation devices, aimed at improving healthcare outcomes for mental and neurodegenerative illnesses. The Gen-2 device is designed to penetrate deeper into the brain using an advanced waveform, while the Gen-3 prototype will utilize a virtual-clinic model for treatment.
Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) provided a business update emphasizing its advancements in neurostimulation devices aimed at combating mental health disorders. The company is enhancing its Gen-1 device to a more powerful Gen-2 model with a waveform increase from 4 milliamps to 15 milliamps, expected to improve treatment efficacy. Plans for FDA submissions and clinical trials are outlined, including a strategy for addressing Major Depressive Disorder. Additionally, Nexalin reports progress with its devices in China and a recent white paper supporting its technology's effectiveness for anxiety treatment.
FAQ
What is the current stock price of Nexalin Tech (NXLIW)?
